A number of included studies demonstrated that BAM-10, BC-10, various formats of RN2N and IVIg were delivered to targeted regions and neurons by a single or repeated FUS-MB treatment and bound to Aβ plaque and phosphorylated tau, inducing immune-mediated response and resulting in reduction of Aβ and tau load in AD animal models [6, 7, 14, 15, 33]. Here, MAPT is linked to Alzheimer disease.